Actively Recruiting
A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Acne Vulgaris
Led by Shanghai Zhongshan Hospital · Updated on 2025-06-05
60
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating dihydroartemisinin (DHA) as a potential treatment for Acne Vulgaris in adults. The study aims to determine if DHA can improve acne severity by at least one grade after treatment. This early phase 1 trial focuses on adults diagnosed with Acne Vulgaris and seeks to understand how DHA may affect their symptoms over a three-month period. Participants will take DHA at a dose of 40 mg three times a day for 90 days. The treatment phase lasts for three months, during which participants will visit the clinic once every month for checkups and tests. This trial does not use masking or blinding and includes only one study group receiving the experimental drug. During the study, participants will undergo assessments including the Investigator's Global Assessment (IGA) of acne severity before and immediately after treatment. Other measures include changes in the Global Acne Grading System (GAGS) score, counts of inflammatory and non-inflammatory lesions, the number of participants reaching low IGA scores, and serum total testosterone levels. These evaluations help researchers monitor how DHA affects acne and related factors over the 90-day treatment period.
CONDITIONS
Brief Title
Efficacy of Dihydroartemisinin for Treating Acne Vulgaris
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically diagnosed with acne vulgaris
- Female patients must have no pregnancy plans within the next 6 months
- Adults aged between 18 and 40 years
You will not qualify if you...
- Use of sex hormones or systemic acne medications within the past 3 months
- Use of topical acne medications within the past 2 weeks
- Pregnant or breastfeeding women
- Known severe diseases of vital organs or malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 90 days
Participants receive dihydroartemisinin 40mg three times daily for acne vulgaris.
1 baseline visit and 1 follow-up visit immediately after treatment
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
L
Lujuan GAO, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here